Results 71 to 80 of about 7,096,396 (300)

The Utility of serological markers in inflammatory bowel diseases: Gadget or magic? [PDF]

open access: yes, 2008
The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly expanding. Anti–Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely investigated ...
Papp, Mária   +3 more
core  

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Pro-Resolving Effect of Ginsenosides as an Anti-Inflammatory Mechanism of Panax ginseng

open access: yesBiomolecules, 2020
Panax ginseng, also known as Korean ginseng, is a famous medicinal plant used for the treatment of many inflammatory diseases. Ginsenosides (ginseng saponins) are the main class of active constituents of ginseng.
Dong-Soon Im
doaj   +1 more source

Anti-Inflammatory Cytokines Predominate in Acute Human Plasmodium knowlesi Infections. [PDF]

open access: yes, 2011
Plasmodium knowlesi has entered the human population of Southeast Asia. Naturally acquired knowlesi malaria is newly described with relatively little available data, including data on the host response to infection.
Parker-Williams, J   +29 more
core   +2 more sources

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages

open access: yesFrontiers in Pharmacology, 2019
Despite the progress that has occurred in recent years in the development of therapies to treat painful and inflammatory diseases, there is still a need for effective and potent analgesics and anti-inflammatory drugs.
Larissa Staurengo-Ferrari   +6 more
doaj   +1 more source

Inhaled corticosteroids in treatment of cystic fibrosis

open access: yes, 2012
Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, anti-inflammatory therapies are often used to decrease the excessive and persistent inflammatory response.
ERDEM ERALP, ELA
core   +1 more source

Marine Anti-inflammatory and Antioxidant Agents 2.0

open access: yes, 2023
The Special Issue “Marine Anti-Inflammatory and Antioxidants Agents 2.0” collects in vitro and/or in vivo experimental investigations highlighting the role of marine-derived bioactive compounds as modulators of inflammation and/or oxidative stress ...

core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy